Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Other 3Genitourinary 2Dermatologic 2CNS 1

Conditions

Melanoma 2Skin Neoplasms 1Prostatic Neoplasms 1Kidney Neoplasms 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Naltrexone × Dermatologic × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01650350 2022-03-04

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Brown University

Phase 2 Terminated
7 enrolled 5 charts
DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡